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Abstract
Estrogens may influence gastric cancer risk but published studies are inconclusive. We therefore
performed a meta-analysis addressing the associations of gastric cancer in women with menstrual
and reproductive factors, and with use of estrogen- and antiestrogen-related therapies. Searches of
PubMed up to June, 2011 and review of citations yielded a total of 28 independent studies
including at least one exposure of interest. Random effects pooled estimates of relative risk (RR)
and corresponding 95% confidence intervals (CI) were calculated for eight exposures reported in
at least five studies, including: age at menarche, age at menopause, years of fertility, parity, age at
first birth, oral contraceptive use, hormone replacement therapy (HRT), and tamoxifen treatment.
Longer years of fertility (RR= 0.74; 95% CI= 0.63 to 0.86) and HRT (RR= 0.77, 95% CI= 0.64 to
0.92) were each associated with decreased gastric cancer risk. Conversely, tamoxifen treatment
was associated with increased risk (RR= 1.82, 95% CI= 1.39 to 2.38). The other five exposures
were not significantly associated. Our analysis supports the hypothesis that longer exposure to
estrogen effects of either ovarian or exogenous origin may decrease risk of gastric cancer.
Additional studies are warranted to extend this finding and to identify the underlying mechanisms.
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BACKGROUND
Gastric cancer represents the fourth most common cancer and the second leading cause of
cancer death worldwide (1). Notably, for most populations in both high and low incidence
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regions, the overall incidence in males is approximately double that of females (2, 3). Since
these sex differences cannot be totally explained by variations in sociodemographic
characteristics, environmental factors or Helicobacter pylori (H. pylori) infection (4, 5),
female sex hormones have been proposed to be protective (6). This hypothesis has been
previously evaluated by examining associations of gastric cancer risk in women with sex
hormone -related exposures, but most individual studies have been inconclusive. To more
precisely characterize the reported associations, we have performed a meta-analysis of these
data.
MATERIALS AND METHODS
We searched for studies published in any language before June 30, 2011 evaluating the
associations of sex hormone-related exposures with gastric cancer incidence or mortality,
using PubMed® software to search Medline (U.S. National Library of Medicine, Bethesda,
MD).
To identify studies of menstrual and reproductive factors, as well as exogenous estrogens,
the following search strategy was used: (gastric cancer OR stomach cancer OR stomach
neoplasms) AND (reproductive factors OR menstrual factors OR age at menarche OR
menarche OR menstruation OR parity OR pregnancy OR breastfeeding OR miscarriage OR
abortion OR fertility OR age at menopause OR estrogens OR sex hormones OR ovariectomy
OR oophorectomy OR hysterectomy OR sex differences OR male predominance OR
exogenous hormones OR oral contraceptives OR hormone replacement therapy OR
menopausal hormone therapy OR climacteric OR reproductive history) AND (risk
assessment OR risk OR risk factors OR epidemiology) AND (case-control studies OR case-
control OR cohort studies OR cohort). Reference lists of the selected papers were also
screened for other potential articles that may have been missed in the database search. If
necessary, we attempted to contact the authors to request additional information.
For the search of tamoxifen studies the following strategy was used: tamoxifen AND
(gastric cancer OR stomach cancer OR stomach neoplasms OR gastrointestinal neoplasms)
AND (case-control studies OR case-control OR cohort studies OR cohort OR longitudinal
studies OR longitudinal OR retrospective studies OR retrospective OR prospective studies
OR prospective OR follow-up studies OR epidemiologic studies). We also searched for data
on primary gastric cancer in randomized clinical trials of tamoxifen therapy for breast cancer
treatment or prevention by combining the following terms: tamoxifen AND (gastric cancer
OR stomach cancer OR stomach neoplasms OR gastrointestinal neoplasms OR “second
cancers” OR “second malignancies” OR neoplasms, second primary[MeSH Terms]) AND
(breast cancer OR breast neoplasms OR breast malignancy) AND (randomized controlled
trial[Publication Type] OR (randomized[Title/Abstract] AND controlled[Title/Abstract]
AND trial[Title/Abstract]) OR random*[Title/Abstract] OR random allocation[MeSH
Terms]). We also reviewed the reference lists of identified articles and of two previous
meta-analyses addressing the associations of tamoxifen therapy with breast cancer
recurrence and with adverse effects (7, 8).
Two investigators in our team independently reviewed the articles and extracted the data;
any disagreement was resolved by consulting a third reviewer. For inclusion in this re-
analysis, the studies had to present adjusted estimates of relative risk (or similar measures of
association including odds ratios; RR), and corresponding 95% confidence intervals (CIs). If
anatomical subsite-specific RRs were reported, we extracted data on noncardia gastric
cancer only. While gastric cancer risk was purportedly increased with tamoxifen exposure
presumed from date of diagnosis in two cancer registry studies (9, 10), we only included
data for known exposure status.
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The following information was recorded for each study: first author, journal, country where
conducted, year of publication, study design, studied outcome, exposure variables and
categories, number of gastric cancer cases, number of controls, cohort size (if applicable),
age range, menopausal status of the participants, duration of follow-up (if applicable), total
person-years of observation (if applicable), treatment regimen (if applicable), adjusted-RR
estimates and 95% CI for incident gastric cancer, and confounding variables controlled.
Pooled risk estimates were calculated for exposure variables that were reported in at least
five studies, which included: age at menarche, age at menopause, years of fertility (defined
as years between menarche and menopause in all but one study, which also omitted periods
of pregnancy (11)), parity, age at first birth, oral contraceptive (OC) use, hormone
replacement therapy (HRT), and tamoxifen treatment.
Other sex hormone-related variables reported in fewer than five studies included: menstrual
regularity, number of pregnancies, age at first pregnancy, breastfeeding of offspring,
spontaneous abortion, induced abortion, oophorectomy, hysterectomy, menopausal status,
intrauterine device use, parenteral contraceptive use, tubal sterilization, duration of OC use,
duration of HRT, and history of endometriosis or vaginosis.
Exposures to exogenous estrogens and tamoxifen therapy were analyzed as dichotomous
variables. Since some studies reported associations for varying durations of OC use as
compared to never use, we pooled those risk estimates using random effects meta-analysis to
estimate the overall effect for ever versus never use. Because the categories of other
exposure measures varied across studies, we performed a meta-analysis of the comparison of
the highest versus the lowest category (or the inverse of the comparison of the lowest versus
the highest category, as applicable) in each study. For two instances in which an adjusted
RR for this comparison was unavailable, we calculated a crude RR (with Fisher exact 95%
CI) from the reported data. Based on the 95% CI, we calculated the standard error (se) for
the ln(RR) by the formula: se=(ln(upper limit) – ln(lower limit))/(2*Z1-α/2), where for a
95% CI, Z1-α/2 equal to 1.96 (12). Pooled RRs with corresponding 95% CI were then
obtained using the random effects method of DerSimonian and Laird, with inverse variance
weights (13). Between-study heterogeneity was assessed for statistical significance using the
Q statistic and quantified with the I2 metric, classified as low (<25%), moderate (25–50%)
and high (>50%) following Higgins et al. (14, 15). If moderate or high heterogeneity was
identified for a given variable, meta-regression techniques were used to examine the extent
to which one or more of the following covariates might be explanatory: study design
(cohort, case-control or randomized clinical trial), continent where conducted (Asia, Europe
or North America), studied outcome (incidence or mortality), menopausal status of the
participants (all post-menopausal or both pre- and post-menopausal), and whether or not the
study adjusted for a proxy variable related to socioeconomic status (SES) such as education,
income or occupation. Galbraith plots were used to identify studies which were major
contributors to heterogeneity (16). Given that SES is inversely associated with gastric cancer
risk (17) and is also an important predictor of HRT use (18), we tried to minimize
confounding with an alternative meta-analysis which excluded three studies that did not
adjust for any SES-related variables.
Since some studies of tamoxifen reported no gastric cancers in one of the treatment groups,
we could not compute individual RR estimates. We therefore summed the gastric cancers
and corresponding person-time for tamoxifen treated and untreated groups, separately for
randomized trials and observational studies. Summary RRs (with Fisher exact 95% CI) were
derived for the two marginal analyses, and then pooled using a random effects meta-
analysis.
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Publication bias was investigated by visual inspection of Begg’s funnel plots and formally
tested using Egger's regression asymmetry method (19, 20). The influence of individual
studies on the overall meta-analysis RR was assessed by sequentially dropping each one
before pooling study-specific RRs. A priori, we considered an influential study to be one for
which its exclusion altered the overall pooled RR by more than 10%.
Statistical analyses were performed with Stata version 11 (StataCorp, College Station, TX)
using a combination of published macros for meta-analysis, including metan, metainf,
metareg, galbr and metabias (21). A p-value ≤ 0.05 was considered statistically significant
for all tests except the heterogeneity and Egger regression tests, for which p<0.1 was
considered significant. All statistical tests were two-sided.
RESULTS
Literature search for menstrual and reproductive factors and exogenous estrogens
The literature search identified 336 publications, for which the titles and abstracts were
scanned to determine potential eligibility for inclusion. Of the 336, 19 were retrieved for
further evaluation that also led to identification of five more citations from their collective
references (Figure 1A). Thus, 24 articles (23 written in English and 1 in Japanese) reported
associations of at least one sex hormone-related variable with gastric cancer risk (11, 22–
44). However, we excluded the articles by Miller et al. (22), Plesko et al. (23), Tsukuma et
al. (24), La Vecchia et al. (25) and Kvale et al. (28) because only point estimates were
reported without 95% CI. Two articles reported partially overlapping data from the Japanese
Collaborative Cohort Study (31, 37); we extracted data from Sakauchi et al. (37), the more
recent reference, for all sex-related variables except years of fertility, which was only
available from Kaneko et al. (31). Two articles from the Shanghai Women’s Health Study
reported overlapping results on OC use (36, 40), so those results were extracted from the
more recent reference (40); other sex-related variables were extracted from Freedman et al.
(36). Two articles reported risk estimates based on the same Italian hospital based case-
control study, so data from the larger sample of Fernandez et al. (32) were used for HRT
whereas other sex-related variables were only available from La Vecchia et al. (26). Two
reports based on the UK General Practice Research Database overlapped (34, 44), so data
from the more recent reference were used (44). Exogenous estrogen exposure in the Japan
Public Health Center-based Prospective Study reported by Persson et al. (38) was excluded
because OC use and HRT were not distinguished. Therefore, a total of 18 articles,
representing 14 independent studies, were included in the meta-analysis (Table 1). All but
two articles reported on gastric cancer incidence as the outcome; the exceptions being two
articles on gastric cancer mortality by Sakauchi et al. (37) and Chang et al. (43). Six studies
had been carried out in Europe, six in Asia, and two in North America. Seven studies
reported case-control comparisons and seven were analyses of cohorts. Five studies were
restricted to post-menopausal women (26, 27, 30, 37, 44) and the remaining nine studies
included both pre- and post-menopausal women. Studies differed with respect to the risk
factors controlled in the original analyses: all studies adjusted for age, seven controlled for
SES-related variables (11, 26, 27, 35, 36, 39, 43), six controlled for body mass index (11,
27, 32, 36, 41, 44), six controlled for smoking (11, 30, 32, 36, 41, 44), four controlled for
family history of gastric cancer (26, 27, 30, 38), six controlled for diet-related variables (11,
26, 27, 30, 35, 41), and five controlled for multiple menstrual or reproductive-related
variables simultaneously (26, 29, 35, 39, 40). However, Frise et al. (35) used premenopausal
as the referent category for age at menopause and Freedman et al. (41) used nulliparous as
the referent category for age at first birth. Hence, these two adjusted RRs could not be
pooled with others comparing the highest versus the lowest categories, so we calculated and
used crude RRs instead.
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Literature search for tamoxifen exposure
The two independent literature searches identified 115 citations that were potentially
relevant to this re-analysis (Figure 1B). Based on the information provided in the title and
abstract, we retrieved for further evaluation 13 articles in which drug therapy in the
treatment arm differed from that in the control arm solely by the use of tamoxifen.
References of these articles and of two previous meta-analyses led to identification of 12
additional studies. Besides irrelevant and duplicate citations, we excluded articles that had
either no cases of gastric cancer or did not distinguish them within larger categories (e.g.,
digestive tract). There were overlapping results from the Danish Breast Cancer Cooperative
Group (45, 46), the Christ Hospital Adjuvant Tamoxifen Trial (47, 48), the B-14 trial (49,
50), and the Stockholm Breast Cancer Study Group (51, 52), so data from the more recent
articles were extracted (46, 48, 50, 52). In addition, two reports based on US cancer
registrations overlapped (53, 54), so data from the longer study period were extracted (53).
Thus, a total of 14 independent studies, including nine randomized trials (48, 50, 52, 55–60)
and five cohorts (46, 53, 61–63), were included in the meta-analysis (Table 2).
Years of fertility
For the analysis of years of fertility, a total of eight studies were identified (11, 26, 27, 30,
31, 35, 36, 38; Figure 2A). Study-specific RRs for the longest versus the shortest duration of
fertility ranged from 0.55 to 0.99. The pooled RR suggested a significant inverse association
with a 26% decreased risk of gastric cancer (Table 3) and low between-study heterogeneity.
The pooled RR was robust to the exclusion of any individual study.
Age at menarche
Associations of gastric cancer with age at menarche were reported in 11 studies (11, 26, 27,
29, 30, 35–38, 41, 42). Study-specific RRs for the oldest age at menarche as compared to the
youngest age ranged from 0.70 to 1.93, and the pooled RR was 1.0 (Table 3). Between-study
heterogeneity was high, but meta-regression analysis of potential explanatory factors failed
to explain the variability. A Galbraith plot (not shown) indicated the studies by Frise et al.
(35) and Persson et al. (38) as outliers contributing to this heterogeneity. The pooled RR
derived with exclusion of those studies was 0.89 (95% CI= 0.80 to 1.0). Notably, analysis
restricted to the same set of studies (n=8) included in the meta-analysis of years of fertility
(including data from Kaneko et al. (31) instead of Sakauchi et al. (37)), had a pooled RR of
1.08 (95% CI= 0.86 to 1.35) for oldest age at menarche as compared to the youngest age,
similar to the effect based on all 11 studies.
Age at menopause
Ten studies examined the association of gastric cancer and age at menopause (11, 26, 27, 29,
30, 35–38, 41). Study-specific RRs for the oldest age at menopause as compared to the
youngest ranged from 0.52 to 1.44. The pooled RR was 0.84 (95% CI= 0.67 to 1.05), with
low heterogeneity across studies. This estimate was robust to the exclusion of any individual
study. The pooled RR was 0.81 (95% CI= 0.62 to 1.06) for the eight studies (including data
from Kaneko et al. (31) instead of Sakauchi et al. (37)) that also reported on years of
fertility.
Parity
Twelve studies provided information on parity (11, 26, 27, 29, 35–39, 41–43), with study-
specific RRs for highest number of full-term pregnancies in comparison to the lowest
ranging from 0.52 to 1.90. The summary RR was 0.94 (95% CI= 0.74 to 1.19). For the five
studies (11, 26, 35, 38, 41) that used nulliparous women as the reference group the pooled
RR was 0.95 (95% CI= 0.66 to 1.38; I2=56.3%), whereas for the other seven that used a
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parous comparison group (either 1 child or 1–2 children), the pooled RR was 0.93 (95% CI=
0.68 to 1.27; I2=89.3%). High heterogeneity was detected among all 12 studies, but there
were no significant explanatory variables in meta-regression analysis. A Galbraith plot (not
shown) identified the studies by La Vecchia et al. (26), Chung et al. (42), and Chang et al.
(43) as outliers contributing to between-study heterogeneity. In an analysis excluding those
three studies, the pooled RR was essentially unchanged at 0.96 (95% CI= 0.85 to 1.07).
Age at first birth
Risk estimates for oldest versus youngest age at first birth were reported in 10 studies (11,
26, 27, 29, 30, 36–39, 41) and ranged from 0.43 to 1.45. The pooled RR was 0.99 (95% CI=
0.85 to 1.15), with low heterogeneity among the studies (Table 3). This estimate was robust
to the exclusion of any individual study.
Oral contraceptive use
Risk estimates for ever vs. never OC use were reported in four studies (26, 35, 40, 42) and
ranged from 0.79 to 2.50. In addition, the studies by Duell et al. (11) and Freedman et al.
(41) reported two to three RRs depending on duration of use, which we pooled to obtain
overall RRs for ever use of 1.18 (95% CI= 0.89 to 1.56) for Duell et al. (11) and 0.85 (95%
CI= 0.54 to 1.34) for Freedman et al. (41). The proportion of OC users ranged from 3% in a
study from Italy using data collected before 1993 (26) to 55% in the European Prospective
Investigation into Cancer and Nutrition Study which included women enrolled from 1992 to
1998 (11). The overall pooled RR of gastric cancer for ever users versus never users of OC
was 1.15 (95% CI=0.71 to 1.88). We found high heterogeneity among the studies, but none
of the available variables significantly explained this variation. A Galbraith plot (not shown)
indicated the studies by Dorjgochoo et al. (40), Freedman et al. (41), and Chung et al. (42)
as outliers contributing to this heterogeneity. The pooled RR derived with exclusion of those
studies was 1.11 (95% CI= 0.87 to 1.42).
Hormone replacement therapy
Figure 2B represents a forest plot of the effect size distribution for the seven studies that
reported on post-menopausal HRT (11, 32, 35–37, 41, 44). The proportion of HRT users
ranged from 4% in China (36) to 55% in the US (41). The pooled RR of gastric cancer for
ever users of HRT as compared to never users was 0.77 (95% CI=0.64 to 0.92), and there
was low heterogeneity among all studies. The average pooled RR was robust to the
exclusion of any one study from the overall meta-analysis. In a sensitivity analysis restricted
to the four studies that adjusted for a proxy variable of SES (11, 32, 35, 36), the point pooled
RR was minimally changed but statistical significance was lost (RR=0.80; 95% CI= 0.60 to
1.06).
Tamoxifen therapy
Table 2 summarizes studies with data for comparison of primary gastric cancer incidence
among women treated or untreated with tamoxifen. Nine randomized controlled trials
including 33,329 patients reported a total of 19 gastric cancer cases in the tamoxifen arms
and 14 in the control arms. Five separate observational cohort studies reported combined
incidence rates of 0.57 and 0.30 gastric cancers per 1,000 patient-years in the tamoxifen-
treated and -untreated groups, respectively. Thus, tamoxifen treatment was associated with a
non-significantly increased risk in the randomized trials (RR= 1.35; 95% CI= 0.64 to 2.92)
and a significantly increased risk in the observational studies (RR= 1.90; 95% CI= 1.41 to
2.52). A meta-analysis of these two marginal RRs (with inverse variance weights of 13%
and 87%, respectively) found a significantly increased gastric cancer risk among women
treated with tamoxifen (RR= 1.82; 95% CI=1.39 to 2.38).
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The p-values for Egger’s test of publication bias were greater than 0.1 for all exposure
variables with the exception of OC use (P= 0.10; Table 3). Figure 2 presents Begg’s funnel
plots for years of fertility (2C) and HRT (2D), the two variables found to be significantly
associated with gastric cancer risk.
DISCUSSION
Although much has been learned about the epidemiology of gastric cancer, it is still unclear
why males have higher risk than females. Our meta-analysis identified decreased gastric
cancer risks among women with longer duration of fertility or exposure to HRT, and
increased risk with exposure to the antiestrogenic agent tamoxifen. However, we found no
significant associations with age at menarche, age at menopause, parity, age at first birth or
OC use. On balance, these findings support the notion that estrogen exposure influences the
risk of gastric cancer in women.
Given the narrow range of age at menarche, variation of years of fertility is mainly
determined by age at menopause. Accordingly, we expected similar associations of gastric
cancer with these latter two variables, at least with restriction to the common set of eight
studies in which both variables were reported. A potential explanation for the discrepancy in
our results, not addressable with aggregated data, may be inconsistency between these
variables in categorizing individuals as having high (or low) exposure within a given study.
The other null associations of our analysis may also be understood in context. OC use is not
a strong risk factor for breast cancer, an estrogen-driven malignancy (64, 65). Hence, it may
not be surprising that OC use does not appear to be associated with gastric cancer risk, for
which estrogen exposure presumably has a smaller role. Furthermore, parity and age at first
birth do not have clear interpretations regarding quantitative exposure to estrogen, so the
failure to find significant associations with these variables is less relevant to the estrogen
hypothesis.
The studies we included vary with respect to the factors controlled in the original analyses.
Although we used the reported multivariable adjusted RRs where available, there may have
been residual confounding. In the case of HRT, it is possible that postmenopausal women
who used hormone therapy may have differed from never users in ways that influence their
risk of gastric cancer. Nevertheless, the four studies that adjusted for these differences with a
proxy variable for SES had a similar pooled RR as all seven studies of HRT. Thus,
confounding by SES would not explain the association between HRT use and gastric cancer,
to the extent that these proxies adequately controlled for SES differences without residual
confounding.
As a selective estrogen receptor modulator, tamoxifen has both anti-estrogenic (e.g., breast
tissue) and estrogenic (e.g., bone) effects (66). In a mouse model of gastric cancer,
tamoxifen upregulated estrogen-responsive pathways and prevented gastric cancer
development (67). We found an opposite effect on risk of gastric cancer in humans, which
may speculatively reflect species differences in gastric epithelial susceptibility to the dual
tamoxifen effects. Additional potential explanations for the inconsistency between animal
and epidemiological studies include differences in relative age, dose and duration of
treatment as well as drug metabolism.
Chronic infection with H. pylori is the primary cause of gastric cancer, and this bacterium is
designated a Class I carcinogen by the World Health Organization (68). Sex differences in
age at acquisition and infection prevalence have been proposed as potential explanations for
Camargo et al. Page 7













differences in gastric cancer incidence between males and females (3, 69, 70). Indeed, a
meta-analysis of international population-based surveys (71) found that males had slightly
higher infection prevalence among adults (adjusted OR= 1.16), but not among children.
Studies measuring spontaneous clearance of H. pylori infection by sex have varied, with
some studies indicating slightly higher seroreversion rates for women than men (72–74)
while others found similar rates (75–77). Regarding therapeutic eradication, no significant
variation by sex has been reported. In sum, the small magnitude of these sex differences in
H. pylori acquisition and clearance cannot fully explain the 2:1 incidence gap.
Steroid-based molecules are incorporated by H. pylori into its membrane lipids and differ in
their potential effects on bacterial survival (78, 79). Free-cholesterol, for example, is
glucosylated after incorporation into H. pylori and acts to inhibit specific T cell responses
(80). In vitro, estradiol is bacteriostatic while progesterone and androstendione are
bactericidal (81). In H. pylori infected insulin-gastrin transgenic (INS-GAS) male mice,
estradiol supplementation results in decreased expression of IFNG, TNFA, and IL1B, and
increased expression of IL10 in the epithelial mucosa. Interestingly, these effects are
associated with attenuation of gastric lesions, and in some models protect against the
development of cancer (67, 82, 83). In addition, infected mice treated with estradiol have
reduced gastric mRNA expression and serum levels of the neutrophil chemo-attractant
CXCL1 (67), suggesting that estradiol may limit mucosal injury caused by activated
netrophils. Another study based on a chemically induced model of gastric cancer found that
estrogen-treated male rats, as well as female rats, have a lower risk than non-treated male
controls (84).
There are several lines of evidence that estrogens may protect against gastric cancer: 1)
estrogens interact with receptors in normal, precancerous and cancerous gastric cells (85,
86), which could regulate the growth and clonal expansion of these cells; 2) CpG islands in
the estrogen receptor gene promoters become hypermethylated with aging, leading to
reduced expression with effects on tumor suppressor activity (87); 3) estrogens increase
expression of trefoil factor family genes, which encode products that protect gastric mucosa
from endogenous and exogenous insults (88); 4) estrogens increase apoptosis in human
gastric cancer cells in vitro (89); 5) estrogens increase the strength of the immune response
to bacterial pathogens by directly blocking expression of caspase-12 (90); 6) estrogens
retard cell migration after simulated “epithelial wounding” in primary cultured cells and
particularly in cancer cell lines (91); 7) high concentrations of plasma isoflavones from
phytoestrogens are associated with decreased risk of gastric cancer (92); 8) polymorphisms
in genes involved in estrogen inactivation and hormone bioavailability have been associated
with gastric cancer risk (93); and 9) men with prostate cancer potentially exposed to
therapeutic exogenous estrogens had a reduced incidence of gastric cancer as compared to
an age-matched reference population (94).
Smoking may facilitate persistence of H. pylori infection (95), increases risk of eradication
failure (96), and is considered to have a causal role in the development of gastric cancer
(97). Thus, sex differences in smoking patterns may contribute to the male predominance of
gastric cancer incidence. However, Freedman et al. (5) found roughly similar male/female
ratios for cancer incidence among smokers and nonsmokers, suggesting that the difference
in smoking does not entirely explain the marked sex difference in gastric cancer risk.
About 9% of gastric cancers harbor Epstein-Barr virus (EBV) infection (98, 99).
Furthermore, tumors in males are more than twice as likely to be EBV-positive than tumors
in females. Given this sex difference in incidence rates overall, the 2-fold sex difference in
EBV positivity implies that the incidence of EBV-positive gastric cancer is four times higher
in males than females.
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Differences in diet between men and women might also be related to sex differences in
gastric cancer incidence. In particular, low consumption of fresh fruits and vegetables may
increase the risk of noncardia tumors (100), and some studies have suggested that women
eat fruits and vegetables both more frequently and in greater quantities than men (101, 102).
Other factors that may potentially explain the higher risk of gastric cancer among males as
compared to females are differences in medication and occupational exposures.
Our analysis was limited by the inconsistent categorization of the exposure variables,
particularly those with more than two strata. As with any meta-analysis, we cannot exclude
the possibility that other studies may have been missed during our literature search, or that
studies that observed null effects were absent from the literature altogether. Nevertheless,
we found little evidence of publication bias. A greater potential concern regarding data
completeness is that some of the published studies on HRT or tamoxifen did not specifically
report incidence of gastric cancer, and many registered tamoxifen trials are still unpublished
(7).
Our inability to detect significant between-study heterogeneity may be due to the
insensitivity of the Q statistic and/or limited sample sizes. Furthermore, insufficient data
precluded analyses for histologic and anatomic subtypes, which might have varying
associations with the reviewed exposures. We were also unable to evaluate HRT formulation
(unopposed estrogen versus estrogen plus progesterone compounds) and duration of therapy.
Our finding about tamoxifen primarily reflects observational studies with unmeasured
confounding of treatment assignment. Nevertheless, limited data from randomized
controlled trials was consistent. The analyses of both the randomized trial and the
observational cohort data were hampered by inclusion of groups with zero events, which we
addressed by marginal analyses. While this analytic approach has recognized limitations
(103), alternative approaches such as continuity corrections also have drawbacks (104).
Furthermore, we could not account for the differences in dose and duration of tamoxifen
treatment among studies. Thus, these results should be interpreted with caution.
We restricted our meta-analysis to associations with overt gastric cancer. However, given
the recognized multistep process of gastric carcinogenesis (105), it is necessary to consider
how estrogens might influence earlier stages such as intestinal metaplasia and dysplasia.
Direct assessment of estrogens would be additionally informative, as studies to date are
almost exclusively based on surrogate measures. Furthermore, the effect of other selective
estrogen receptor modulating drugs on gastric carcinogenesis could be usefully examined.
In conclusion, our results are consistent with the hypothesis that estrogen’s effects may
lower the risk of gastric cancer in women. Further studies are needed to extend these
observations and identify the biologic bases of this epidemiologic association. Better
understanding of how sex differences influence carcinogenesis would provide important
insights into gastric cancer etiology.
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Flow diagram of the literature search for studies of (A) menstrual and reproductive factors
and exogenous hormones and (B) tamoxifen.
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Panels A and B. Random-effects estimates and 95% confidence intervals (CI) of gastric
cancer relative risk (RR) associated with (A) years of fertility (highest vs. lowest category)
and (B) hormone replacement therapy (ever vs. never). Study-specific RRs are shown as
squares, with the size of the symbol inversely proportional to the study-specific variance.
Pooled RRs are shown as diamonds, with the middle corresponding to the point estimate and
the width representing the 95% CI.
Panels C and D. Begg’s funnel plots with pseudo 95% CIs for gastric cancer RRs
associated with (C) years of fertility and (D) hormone replacement therapy.
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